Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dawn Qingqing Chong"'
Autor:
Peh Joo Ho, Iain BeeHuat Tan, Dawn Qingqing Chong, Chiea Chuen Khor, Jian-Min Yuan, Woon-Puay Koh, Rajkumar Dorajoo, Jingmei Li
Publikováno v:
eLife, Vol 12 (2023)
Background: To evaluate the utility of polygenic risk scores (PRSs) in identifying high-risk individuals, different publicly available PRSs for breast (n=85), prostate (n=37), colorectal (n=22), and lung cancers (n=11) were examined in a prospective
Externí odkaz:
https://doaj.org/article/235feb946f6444f6887e060a99e8a690
Autor:
Peh Joo Ho, Iain BeeHuat Tan, Dawn Qingqing Chong, Chiea Chuen Khor, Jian-Min Yuan, Woon-Puay Koh, Rajkumar Dorajoo, Jingmei Li
Background:To evaluate the utility of polygenic risk scores (PRSs) in identifying high-risk individuals, different publicly available PRSs for breast (n=85), prostate (n=37), colorectal (n=22), and lung cancers (n=11) were examined in a prospective s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4424549a12a97ae0aa7a223d8e90b64d
https://doi.org/10.1101/2022.09.12.22279874
https://doi.org/10.1101/2022.09.12.22279874
Autor:
Elsie Cheruba, Ramya Viswanathan, Pui-Mun Wong, Howard John Womersley, Shuting Han, Brenda Tay, Yiting Lau, Anna Gan, Polly S. Y. Poon, Anders Skanderup, Sarah B. Ng, Aik Yong Chok, Dawn Qingqing Chong, Iain Beehuat Tan, Lih Feng Cheow
Publikováno v:
Science advances. 8(36)
Genome-wide analysis of cell-free DNA methylation profile is a promising approach for sensitive and specific detection of many cancers. However, scaling such assays for clinical translation is impractical because of the high cost of whole-genome bisu
Autor:
Ignasius Joanito, Pratyaksha Wirapati, Nancy Zhao, Zahid Nawaz, Grace Yeo, Fiona Lee, Christine L. P. Eng, Dominique Camat Macalinao, Merve Kahraman, Harini Srinivasan, Vairavan Lakshmanan, Sara Verbandt, Petros Tsantoulis, Nicole Gunn, Prasanna Nori Venkatesh, Zhong Wee Poh, Rahul Nahar, Hsueh Ling Janice Oh, Jia Min Loo, Shumei Chia, Lih Feng Cheow, Elsie Cheruba, Michael Thomas Wong, Lindsay Kua, Clarinda Chua, Andy Nguyen, Justin Golovan, Anna Gan, Wan-Jun Lim, Yu Amanda Guo, Choon Kong Yap, Brenda Tay, Yourae Hong, Dawn Qingqing Chong, Aik-Yong Chok, Woong-Yang Park, Shuting Han, Mei Huan Chang, Isaac Seow-En, Cherylin Fu, Ronnie Mathew, Ee-Lin Toh, Lewis Z. Hong, Anders Jacobsen Skanderup, Ramanuj DasGupta, Chin-Ann Johnny Ong, Kiat Hon Lim, Emile K. W. Tan, Si-Lin Koo, Wei Qiang Leow, Sabine Tejpar, Shyam Prabhakar, Iain Beehuat Tan
Publikováno v:
Nature genetics. 54(7)
The consensus molecular subtype (CMS) classification of colorectal cancer is based on bulk transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed 373,058 single-cell transcriptomes from 63 patients, focusing on 49,155
Autor:
Aik Yong Chok, David B. Matchar, Sungwon Yoon, Dawn Qingqing Chong, Isaac Seow-En, Emile Kwong-Wei Tan
Publikováno v:
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and IrelandREFERENCES. 23(9)
Aim As populations age and cancer management improves, long-term survivorship and quality-of-life (QOL) outcomes are becoming equally important as oncological results. Data from Asian populations are scarce. We aimed to evaluate the sexual health, ga
Publikováno v:
HealthCom
Colorectal cancer is among the top three most commonly occurring cancers worldwide, and around 30-40% of patients treated by curative intent surgery will experience cancer recurrence. Proactive prognostication would enable clinicians to better plan t
Autor:
Justina Yick Ching Lam, Clarinda Chua, Matthew C.H. Ng, Iain Beehuat Tan, Christabel Jing Zhi Lee, Soo Fan Ang, Patrick Tze Hern Teo, David Wai-Meng Tai, Wen Hsin Koo, Su Pin Choo, Dawn Qingqing Chong, Samuel Cheng En Ee, Simon Ong, Chee Kian Tham
Publikováno v:
Asia-Pacific journal of clinical oncologyREFERENCES. 16(1)
Aim The survival benefit of using a non-cross resistant second-line chemotherapy in the third-line setting in metastatic gastroesophageal cancer is unproven. We evaluated the utility of third-line chemotherapy in patients treated at a single institut
Publikováno v:
Contemporary Clinical Trials. 36:605-615
Currently, only one drug, sorafenib, is FDA approved for the treatment of advanced hepatocellular carcinoma (HCC), achieving modest objective response rates while still conferring an overall survival benefit. Unlike other solid tumors, no oncogenic a
Autor:
Sze Huey Tan, Keith Hsiu Chin Lim, Siew Ju See, Chee Kian Tham, Eu Tiong Chua, Dawn Qingqing Chong, Wai Hoe Ng, John C. Thomas
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 9:220-225
Aim Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma. However, there is no prospective randomized data available that proves the efficacy of the combination for anaplastic glioma. In this